PARIS, France – September 23, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing ...
The issuer is solely responsible for the content of this announcement. Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback